Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: Study protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Edwards, Tansy ^a   Omollo, Raymond ^b   Khalil, Eltahir A G ^c   Yifru, Sisay ^d   Musa, Brima ^c   Musa, Ahmed ^c   Wasunna, Monique ^b   Smith, Peter G ^a   Royce, Catherine ^e   Ellis, Sally ^e   Balasegaram, Manica ^e   Hailu, Asrat ^f  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c UNIVERSITY OF KHARTOUM   (Sudan)

^d UNIVERSITY OF GONDAR   (Ethiopia)

^e Drugs for Neglected Diseases Initiative   (Switzerland)

^f ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN B; ANTIPROTOZOAL AGENT;

AFRICA; ARTICLE; BONE MARROW; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SPLEEN; VISCERAL LEISHMANIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; TIME; TREATMENT OUTCOME;

AFRICA, EASTERN; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; LEISHMANIASIS, VISCERAL; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952199740     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-66     Document Type: Article

References (23)

1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996, 14:417-423. 10.1016/0738-081X(96)00057-0, 8889319.
2. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010, 10:184-194. 10.1016/S1473-3099(10)70011-6, 20185097.
3. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996, 25:862-871. 10.1093/ije/25.4.862, 8921468.
4. Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 2001, 95(Suppl 1):S27-58. 10.1016/S0035-9203(01)90218-4, 11370250.
5. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001, 323:419-422. 10.1136/bmj.323.7310.419, 37549, 11520836.
6. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010, 362:504-512. 10.1056/NEJMoa0903627, 20147716.
7. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008, 47:1000-1006. 10.1086/591972, 18781879.
8. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998, 76:25-32. 2305623, 9615494.
9. Gilead Sciences Ltd AmBisome: Summary of Product Characteristics 2008, Granta Park, Abington, Cambridge, CB21 6GT, UK, Gilead Sciences Ltd.
10. Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis 2010, 4:e709. 10.1371/journal.pntd.0000709, 2964287, 21049059.
11. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996, 313:36-39. 2351444, 8664772.
12. Kirkwood B, Sterne J. Essential Medical Statistics 2003, Blackwell Science Ltd, Second.
13. Ryan P. sxd1. Random allocation of treatments in blocks. Stata Technical Bulletin 1998, STB-41:43-46.
14. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006, 43:917-924. 10.1086/507530, 16941377.
15. Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001, 17:67-70. 10.1016/S0924-8579(00)00312-5, 11137652.
16. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003, 37:800-804. 10.1086/377542, 12955641.
17. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007, 45:556-561. 10.1086/520665, 17682988.
18. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events Version 3.0 DCTD, NCI, NIH, DHHS. Publish Date: August 9 2006. , http://ctep.cancer.gov
19. TDR Special Programme for Research and Training in Tropical Diseases 2005: Operational Guidelines for the Establishment and Functioning of Data and Safety Monitoring Boards. , http://apps.who.int/tdr/svc/publications/tdr-research-publications/operational-guidelines
20. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). , http://www.ich.org/
21. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. , http://www.wma.net/en/30publications/10policies/b3/17c.pdf
22. Akaza Research Massachusetts USA 2003, Akaza Research Massachusetts USA., http://www.openclinica.org
23. StataCorp LP College Station Texas 77845 USA 1996, StataCorp LP College Station Texas 77845 USA., http://www.stata.com